NCT04652492

Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

A Multicentric, Open-Label Study to Evaluate Tislelizumab in Combination With Transarterial Chemoembolization as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Zhongda Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A multicentric, open-label, single-arm prospective study to assess the efficacy and safety of tislelizumab combined with TACE as first-line treatment in patients with unresectable BCLC stage C HCC.

Detailed description

This is a multicentric, open-label, single-arm prospective study to assess the efficacy and safety of tislelizumab combined with conventional transarterial chemoembolization(cTACE) as first-line treatment in BCLC stage C HCC patients without extrahepatic spread. The primary endpoint is time to progression (TTP).

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Tislelizumab in combination with cTACE	On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)

Timeline

• Start date: 2020-10-27
• Primary completion: 2022-11-01
• Completion: 2023-11-01
• First posted: 2020-12-03
• Last updated: 2020-12-03

Locations

1 site across 1 country: China